Current Status and Future Prospects of Treatment for EGFR-Positive Non-Small Cell Lung Cancer After Resistance to EGFR-TKI
EGFR-mutant non-small cell lung cancer (NSCLC) is a common type of lung cancer, with EGFR tyrosine kinase inhibitors (EGFR-TKIs) being the standard first-line treatment. However, most patients with NSCLC eventually develop resistance to EGFR-TKIs. Studies on the mechanism underlying EGFR-TKI resista...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Magazine House of Cancer Research on Prevention and Treatment
2025-06-01
|
| Series: | Zhongliu Fangzhi Yanjiu |
| Subjects: | |
| Online Access: | http://www.zlfzyj.com/cn/article/doi/10.3971/j.issn.1000-8578.2025.24.1209 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|